Science News
from research organizations

Promising new option for first line of attack in lymphoma

Date:
February 25, 2014
Source:
Manchester University
Summary:
Follicular lymphoma is a type of non-Hodgkin’s lymphoma -– a blood cancer -- that usually develops slowly. The majority of patients are diagnosed when their disease is at an advanced stage. Recent improvements in treatment have included the use of antibodies to specifically target the tumor cells and to stimulate the patient’s own immune system to attack their tumor. The use of such antibodies has improved treatment response, but unfortunately most patients still relapse Radioimmunotherapy -- where a radioactive substance is attached to the antibody -- has been shown to be successful in treating patients who had previously relapsed.
Share:
       
FULL STORY

A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma.

Follicular lymphoma is a type of non-Hodgkin's lymphoma- a blood cancer -- that usually develops slowly. The majority of patients are diagnosed when their disease is at an advanced stage.

Recent improvements in treatment have included the use of antibodies to specifically target the tumor cells and to stimulate the patient's own immune system to attack their tumor.

The use of such antibodies has improved treatment response, but unfortunately most patients still relapse.

Radioimmunotherapy -- where a radioactive substance is attached to the antibody -- has been shown to be successful in treating patients who had previously relapsed.

Now a team involving researchers from The University of Manchester -- part of the Manchester Cancer Research Centre -- has investigated the use of radioimmunotherapy treatment in newly diagnosed patients.

The study published in the Journal of Clinical Oncology, looked at the effect of delivering the treatment in two fractions or doses -- this approach is thought to improve the penetration of the drug within larger tumors and also helps reduce the side effects associated with a full dose treatment.

Professor Tim Illidge, who led the research, said: "This was the first study to look at giving two fractions of radioimmunotherapy as an initial treatment in follicular lymphoma. We wanted to assess its safety and effectiveness in a group of high-risk patients who conventionally have done less well."

The researchers found that that their treatment plan was feasible and safe, with very few side effects.

"We saw a high overall response rate, of 94.4%, and 50 of the 72 (69.4%) patients treated in the study achieved complete response -- meaning their symptoms disappeared. These results are encouraging, but we need further studies in larger numbers of patients to fully compare this treatment to the standard treatment of 6-8 cycles of chemotherapy," added Professor Illidge.


Story Source:

The above story is based on materials provided by Manchester University. Note: Materials may be edited for content and length.


Journal Reference:

  1. T. M. Illidge, S. Mayes, R. Pettengell, A. T. Bates, M. Bayne, J. A. Radford, W. D. J. Ryder, S. Le Gouill, F. Jardin, J. Tipping, M. Zivanovic, F. Kraeber-Bodere, M. Bardies, C. Bodet-Milin, E. Malek, D. Huglo, F. Morschhauser. Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. Journal of Clinical Oncology, 2013; 32 (3): 212 DOI: 10.1200/JCO.2013.50.3110

Cite This Page:

Manchester University. "Promising new option for first line of attack in lymphoma." ScienceDaily. ScienceDaily, 25 February 2014. <www.sciencedaily.com/releases/2014/02/140225101250.htm>.
Manchester University. (2014, February 25). Promising new option for first line of attack in lymphoma. ScienceDaily. Retrieved May 26, 2015 from www.sciencedaily.com/releases/2014/02/140225101250.htm
Manchester University. "Promising new option for first line of attack in lymphoma." ScienceDaily. www.sciencedaily.com/releases/2014/02/140225101250.htm (accessed May 26, 2015).

Share This Page: